DAP.F DANAHER CORP. R
Healthcare · Diagnostics & Research
181.10
+4.99%
About the company
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
52-week range
Dividend deep dive
DANAHER CORP., a Healthcare company in Diagnostics & Research with a market cap of EUR 120,250,228,736.0, currently offers a dividend yield of 0.79%. This yield is above its 5-year high of 0.62%, suggesting potential undervaluation according to Yield Theory. The dividend safety is currently assessed as 'safe'. The company is structured to pay dividends quarterly.
Dividend history
DANAHER CORP. has a dividend increase streak of 1 year. Its dividend has grown at a 3-year CAGR of 8.58% and a 5-year CAGR of 12.20%. Annual dividends per share have progressed from EUR 0.3496 in 2014 to EUR 0.9438 in 2023. The projected dividend for 2025 is EUR 1.1186. Dividends are paid quarterly, in March, June, September, October, and December.
Dividend safety
The dividend appears well-covered with a payout ratio of 31.06% against earnings per share of EUR 4.54. DANAHER CORP.
Quantic · Free
Read the rest of the safety verdict
Plus the key risks and what to watch next — free, no card.
AI-generated from Quantic's dividend data · Updated 17 Jul 2026 · Information, not financial advice.
Price history
Dividend profile
Payment calendar
Dividend history
Per-share dividend by year
Debt & leverage
Latest reported balance-sheet figures.
Held by 1 investor
Appears in these lists
DAP.F qualifies for these curated dividend rankings.
New to dividend investing?
Information, not financial advice.
Quantic · Free
Track DAP.F and your whole portfolio
Real yield, dividend safety, net-of-tax income and your path to freedom — free, no broker connection.
Need more? Pro adds portfolios, options income tracking & more AI. See Pro →